<a href="https://laohu8.com/S/OPTHF">Optimi Health</a> Corp. Secures Regulatory Approval for Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Optimi Health Corp., a Canadian manufacturer of GMP psychedelic medicines, has announced the commercial launch of its natural psilocybin capsules in Australia. This approval allows the capsules, which are prescribed for Treatment-Resistant Depression (TRD), to be distributed under Australia's Authorised Prescriber Scheme. The initial shipment included 1,000 capsules, each containing 5mg of naturally-derived psilocybin, manufactured at Optimi's GMP-licensed facility in British Columbia. The launch follows successful MDMA sales for PTSD treatment in Australia, marking a significant step for Optimi in delivering scalable psychedelic treatments. Optimi's authorized commercial partner, Mind Medicine Australia, will oversee distribution and patient coordination through the country's network of clinics and hospitals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 264871) on September 03, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。